NousCom strategy stems from recent achievements in the fields of checkpoint inhibitors, therapeutic antibodies, cancer vaccines and oncolytic viruses.

We plan to develop a series of new, potent immunotherapeutics capable of selectively killing tumor cells, with the expectation to potentiate existing immunotherapies.

Our platform technology is based on three different viral vectors as a powerful toolkit to induce broad and potent anti-cancer T cell responses.